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Background: Pulmonary complications after hematopoietic
stem cell transplantation (HSCT) are common, and manage-
ment may include a bronchoalveolar lavage (BAL). We reviewed
the medical records of patients (pts) who underwent a BAL and
HSCT at our institution from 1990 to 2002 to determine the
success of BAL and identify factors that may alter the diagnostic
yield of the procedure. Methods: Of 917 pts undergoing HSCT
during this period, 90 pts underwent BAL after HSCT. Multiple
data points were analyzed to determine factors that may identify
a patient population more or less likely to have a diagnostic yield
from a BAL. Results: 114 procedures were performed during
this period. The mean age was 12.5 years (range 0.75–26.2
years). For those who had more than 1 BAL performed, only the
ﬁrst procedure was included in the analysis. The BAL was
performed at a mean of 93 days post-HSCT (range 6–730 days).
The 3 most common signs/symptoms leading to the procedure
were fever (56.7%), hypoxia (48.9%), and abnormal chest aus-
cultation (44.4%). Prior to BAL, 88 pts had radiological imag-
ing; 82 pts (93%) had abnormal ﬁndings. The most common
pre-BAL diagnosis was pneumonia (43.3%) followed by respi-
ratory distress (14.4%). Twenty-nine pts (32.2%) had a negative
BAL. The most common ﬁnding was a bacterial infection
(58.9%), followed by an inﬂammatory process (18.9%), viral
infection (13.3%), and alveolar hemorrhage (12.2%). Of the 44
pts who had concurrent infections, 34 (77%) had positive BAL;
82.2% of pts did not experience any procedural complications,
and 10% experienced hypoxia, generally transient. Sixty-seven
pts were receiving immunosuppressive therapy (IST) at the time
of BAL. Twenty-seven of twenty-nine (93.1%) pts who had a
negative BAL were receiving IST compared to 40/61 (65.6%)
pts who had a positive BAL and were on IST (P  .0046).
Furthermore, the proportion of pts who had grade 2–4 acute
graft-versus-host disease (GVHD) was signiﬁcantly higher in
the BAL negative population (13/29  44.8%) than the BAL
positive group (14/61  23%) [P  .0487]. No other prognostic
factors were identiﬁed for those with grade 2–4 GVHD. Con-
clusions: In our experience, performing a BAL after HSCT is
safe. For patients with grade 2–4 acute GVHD or receiving
IST, the likelihood of a respiratory etiology being identiﬁed by
BAL is lower than those without these risk factors. Therefore, in
this particular patient population, a BAL is less likely to have a
diagnostic yield and may not impact therapy.
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ASSESSMENT OF SYMPTOMS AND SYMPTOM BURDEN BEFORE AND
AFTER ENGRAFTMENT DURING ALLOGENEIC BLOOD OR MARROW
TRANSPLANT (BMT)
Williams, L.A.1, Wang, X.S.1, Cleeland, C.S.1, Mobley, G.1, Giralt, S.1
University of Texas M. D. Anderson Cancer Center, Houston, TX.
Symptom burden (SB) is the combined impact of all disease- or
therapy-related symptoms on one’s ability to function as one did
before onset of disease or therapy. Patient report of symptoms
following BMT is not well-described. Lack of understanding of
symptoms and SB may result in failure to address symptoms and
return patients to optimum functioning. Purpose: To describe
symptoms and SB in AML/MDS patients undergoing allogeneic
BMT before and after neutrophil engraftment (ﬁrst of 3 consecu-
tive days ANC  500 cells/mm3). Methods: 30 patients with a
mean age of 52.9 years (SD  9.6) rated 19 symptoms on a 0–10
scale twice weekly from baseline before the start of conditioning to
28 days post-BMT using the M. D. Anderson Symptom Inventory.
Results: Mean global symptom severity (GSS) peaked at day 11
post-BMT. The 7 most severe symptoms on day 11 were pain,
drowsiness, lack of appetite, dry mouth, mouth sores, physical
weakness, and fatigue. Mean symptom intensity scores and SDs are
reported in Table 1. There was a signiﬁcant difference (t  4.34,
P .001) between mean GSS at baseline and day11. Neutrophil
engraftment occurred on average 13.7 days (SD  3.00) post-
BMT. There was no signiﬁcant difference (t  0.75, P  .455) in
mean GSS from day 11 to day 15, the ﬁrst post-engraftment
assessment. Mean GSS declined by day 29, but the difference
between the mean GSS on day 11 and day 29 was not signif-
icant (t 1.92, P .060). At day15, only mean pain severity had
declined signiﬁcantly (t  2.48, P  .016) from day 11. At day
29, mean pain and mouth sores severity had declined signiﬁcantly
(t  4.46, P  .001 and t  2.26, P  .031, respectively) from day
11. Conclusions: Patients report various symptoms post-alloge-
neic BMT, with the most severe involving pain, the upper GI tract,
fatigue, and weakness. After engraftment, pain severity declines
rapidly, GI symptoms decline more slowly, and fatigue and weak-
ness do not decline. Most symptoms have not declined signiﬁcantly
a month post-BMT and patients remain burdened by symptoms.
Clinicians should verify with patients the symptoms they are ex-
periencing and intervene to control them. Further research in SB
and in the causative mechanisms of symptoms is needed to improve
BMT treatment outcomes.
Table 1. Mean Symptom Severity Scores
Baseline Day 11 Day 15 Day 29
Symptom Mean, SD Mean, SD Mean, SD Mean, SD
GSS 1.32,1.38 3.08,1.74 2.72,1.91 2.24,1.59
Pain 1.80,2.91 5.30,2.68 3.52,2.84 2.29,2.45
Drowsiness 1.87,2.50 5.20,2.89 4.48,3.00 3.75,3.08
Lack of appetite 1.10,2.22 4.57,3.18 4.14,3.32 3.18,2.88
Dry mouth 0.87,1.61 4.52,3.21 3.97,3.52 2.93,3.21
Mouth sores 0.03,0.18 4.50,3.95 2.93,3.21 0.82,2.06
Physical weakness 2.03,2.55 4.37,2.86 3.83,2.90 3.96,2.76
Fatigue 3.00,2.29 4.20,2.57 4.41,2.78 4.46,2.82
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A CLINICAL ALGORITHM FOR CIDOFOVIR TREATMENT OF ADENOVIRAL
INFECTIONS IN PEDIATRIC ONCOLOGY AND BONE MARROW TRANS-
PLANT PATIENTS: A REPORT OF DIRECTED, SAFE AND EFFECTIVE
CIDOFOVIR USE
Williams, K.M.1, Agwu, A.L.2, Dabb, A.A.3, Higman, M.A.1,
Loeb, D.M.1, Chen, A.R.1 1. Department of Pediatric Oncology, The
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital,
Baltimore, MD; 2. Department of Pediatric Infectious Diseases, Johns
Hopkins Hospital, Baltimore, MD; 3. Department of Pharmacy, Johns
Hopkins Hospital, Baltimore, MD.
Adenoviral infections cause signiﬁcant mortality in bone marrow
transplant (BMT) patients and those with protracted therapy-
induced leukopenia. The mortality from adenovirus in the BMT
population approaches 60% and fatalities have been reported in
oncology patients. Cidofovir (CDV) has emerged as a promising
therapy for adenovirus infection, though its efﬁcacy is reported as
low as 31% with renal toxicity up to 50%. There are no published
clinical algorithms guiding initiation of therapy, and the efﬁcacy
and safety of CDV in pediatric oncology patients are ill-deﬁned. A
clinical algorithm was developed reserving CDV therapy for high-
risk patients, deﬁned as: (1) a BMT patient or a patient with
prolonged leukopenia and (2) evidence of dissemination (blood
PCR or recovery of adenovirus from two or more sites) or
evidence of invasive disease (symptoms associated with the site of
adenoviral disease). A retrospective review of pediatric oncology
and BMT patients with adenoviral infection between July 2001 and
July 2004 captured 20 patients: 9 allogeneic BMT, 3 autologous
BMT, and 8 non-BMT. Using the algorithm, 14 were high risk. Of
these, 9 were treated with CDV. All initially cleared their adeno-
virus though 1 died of fungal infection after recrudescence of
adenovirus. All 5 high-risk CDV untreated patients died, 4 with
disseminated adenovirus. CDV treatment signiﬁcantly reduced ad-
enovirus-related mortality in the high-risk group (RR 0.14, P 
.05). Graft-versus-host disease (GVHD) and hemolytic-uremic
syndrome (HUS) were associated with negative outcomes. All 4
patients with HUS died. Seventy-ﬁve percent of those who died
had severe GVHD. The overall mortality was 45% (9/20), of
which 67% (6/9) was due to adenoviral disease, primarily among
high risk, untreated (5/6) patients. All 6 low-risk patients cleared
their infection without CDV treatment, but one recrudesced and
died of adenoviral disease; he met criteria for treatment at recru-
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descence. None of the treated patients had CDV-related nephro-
toxicity, although one patient had severe renal impairment prior to
CDV therapy (Table1). CDV is a safe and effective therapy for
adenoviral disease in pediatric oncology and BMT patients. We
present a novel algorithm that identiﬁed patients at high-risk for
severe adenoviral disease who would beneﬁt from CDV therapy. In
addition to GVHD, we propose HUS may be associated with
severe adenoviral disease in this popuation.
Table 1.
Risk
Cidofovir
Therapy n
Adenovirus
Clearance N (%)
Adenoviral-
Related
Mortality
N(%)/RR
Overall
Mortality
N(%)
HIGH
14(70%)
Treated 9 8 (89%) 1 (11%)
0.14
3 (33%)
Untreated 5 1 (20%) 4 (80%) 1 5 (100%)
LOW 6
(30%)
Treated 0 N/A N/A N/A
Untreated 6 6 (100%) 1
recrudescence
1 (17%) 1 (17%)
391
MORTALITY IN BLOOD AND MARROW TRANSPLANTATION: IS THE
POSTMORTEM A DYING PROCEDURE?
Seftel, M.D.1,2,3, Ho, M.3, Demers, A.2,3, Kawaleski, S.1,2,
Bow, E.J.1,2,3, Rubinger, M.1,2,3, Schacter, B.1,2,3, Woloschuk, D.1,3,
Bredeson, C.1,3 1. Manitoba Blood and Marrow Transplant Program,
Winnipeg, MB, Canada; 2. CancerCare Manitoba, Winnipeg, MB,
Canada; 3. University of Manitoba, Winnipeg, MB, Canada.
Introduction: Little is known about post-mortem (PM) char-
acteristics in blood and marrow transplantation (BMT), includ-
ing the variables that predict the decision to perform the PM,
and whether meaningful information is obtained from the PM.
We performed a comprehensive analysis of PMs performed at
our center in order to determine PM rates, temporal trends, and
the utility of this investigation. Methods: All deceased patients
since the BMT program inception in 1990 until 2004 were
analyzed by computerized database and chart review. Patients
(pts) undergoing PM were compared to non-PM deceased pts.
PM reports were graded as to whether they showed major,
minor, or no disagreement with the ante-mortem diagnoses. PM
rates were compared to those of the general hospital population.
Results: Of the 476 pts undergoing myeloablative BMT, 225
died and 48 (27%) underwent PM, of which 41(85%) were full
and 7(15%) limited. The 48 PM pts had a median age of 44 years
(range) (18–63) and only 11 (23%) were post autologous BMT.
Forty-four PM pts (92%) died either on the transplant ward or
the ICU. The performance of a PM was more likely in pts dying
100 days post BMT (P  .001), with acute GVHD (P  .03),
in the ICU (P  .001), and after allografting (P  .001). PM
rates declined signiﬁcantly between the periods 1990–1994,
1995–1999, and 2000–2004 (P  .001). PM was more likely if
death occurred outside of ofﬁce hours (P  .02). The PM rate
at the general hospital was 21%, and showed a similar downward
temporal trend. Major, minor, and no disagreements at PM
were present in 22 (46%), 8(17%), and 18 (37%) of cases.
Conclusions: Despite 46% major disagreement between ante-
and postmortem diagnoses, rates for this procedure are falling in
concert with an overall reduction of PM in hospitalized pts.
Deaths occuring after 100 days post BMT and those outside of
a high care setting are less likely to undergo PM. As BMT pts
remain complex and liable to an extensive array of treatment and
disease-related complications, it is recommended that the PM
regains its role as a valuable investigation. This is especially
relevant in era of older and more inﬁrm pts undergoing non-
myeloablative BMT.
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VALGANCICLOVIR IS EFFECTIVE IN THE PREEMPTIVE TREATMENT OF
CYTOMEGALOVIRUS (CMV) INFECTION AFTER ALLOGENEIC STEM
CELL TRANSPLANT (ASCT)
Aberle, M.F.2, Bachier, C.1, Lemaistre, F.C.1, Shaughnessy, P.J.1 1.
Texas Transplant Institute, San Antonio, TX; 2. Methodist Hospital
System, San Antonio, TX.
Background: CMV infection can cause life-threatening compli-
cations in allogeneic stem cell transplant patients. Preemptive
treatment with ganciclovir is effective for patients with CMV
infection following ASCT. Valganciclovir is a valine esther of
ganciclovir with improved bioavailability. Methods: A retrospec-
tive analysis of ASCT patients receiving preemptive therapy with
ganciclovir or valganciclovir for treatment of CMV infection.
CMV infection was deﬁned as a titer of greater than 5 pg/ul using
the digene hybrid capture CMV-DNA assay. Results: A total of
144 patients received ASCT between January of 2001 and Septem-
ber of 2005. Of these, 39 received preemptive treatment with
valganciclovir (21), ganciclovir (13), or a combination of both
drugs (5). A total of 13 patients received preemptive therapy with
ganciclovir. All 13 patients were seropositive for CMV. Donor
source was: bone marrow (bm)  3, peripheral blood (pb)  10,
match unrelated donors (mud)  3, matched related sibling
(mrs)  10. Conditioning regimens included: reduced intensity
(rit)  5, ablative  8. Thirteen of thirteen patients were on
steroids for treatment of graft-versus-host disease (GVHD). Pa-
tients developed CMV infection on days 4 to 349 (median 
46) after ASCT. The peak CMV-DNA titer was 5.7 to 288 pg/ul
(median 48.65 pg/ul). Twelve of thirteen patients responded to
treatment. The time to response to treatment occurred 5 to 28 days
(median 13) after initiation of ganciclovir. One patient died from
interstitial pneumonitis related to CMV. Six patients received
maintenance therapy with valganciclovir and 3 patient developed
reactivation of their CMV viremia 69–84 days after their ﬁrst
infection.
A total 21 patients received preemptive treatment with valganci-
clovir. Donor source was pb  15, bm 6; mud  14, mrs  7 .
Nineteen patients were seropositive for CMV (2 seronegative pa-
tients with seropositive donor). Conditioning regimens included:
rit  6, ablative  15. Eighteen of twenty-one patients were on
steroids for treatment of GVHD. Patients developed CMV infec-
tion on days 11 to 700 (median  32 after ASCT). The peak
CMV-DNA titer was 2.1 to 149.3 pg/ul (median  26 pg/ul).
Twenty-one of twenty-one patients responded to preemptive ther-
apy with valganciclovir. The time to response to treatment oc-
curred 3 to 34 days (median  10) after initiation of valganciclovir.
Four patients developed CMV reactivation at 88–127 days after
the ﬁrst infection. Conclusions: Valganciclovir is comparable to
ganciclovir for the treatment of CMV infection.
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ALTERNATE DAY GANCICLOVIR AND FOSCARNET IS SAFE AND EFFEC-
TIVE IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTIONS IN AT-
RISK PEDIATRIC AND ADOLESCENT ALLOGENEIC STEM CELL TRANS-
PLANT RECIPIENTS
Shereck, E.1, Militano, O.2, Cooney, E.1, van de Ven, C.1,
Cheung, Y.K.K.3, Del Toro, G.1, Bradley, B.1, George, D.1, Garvin, J.1,
Hawks, R.1, Wischover, C.1, Wolownick, K.1, Schwartz, J.4,
Della-Lotta, P.4, Cairo, M.S.1,4,5 1. Department of Pediatrics; 2. De-
partment of Pharmacy; 3. Division of Biostatistics; 4. Deptartment of
Pathology; 5. Deptartment of Medicine, Morgan Stanley Children’s
Hospital of NewYork-Presbyterian, Columbia University, New York,
NY.
CMV prophylaxis with ganciclovir (Gan) post AlloSCT reduces
the incidence of CMV disease to 3%, but is associated with a
30% incidence of grade III/IV hematologic toxicity (Goodrich et al
NEJM. 1991). Foscarnet (Fos) is effective against CMV, but has
dose limiting renal toxicity (Deray et al Am J nephrol. 1989).
Combination Gan/Fos is more effective than monotherapy in
CMV retinitis in HIV patients (Peters et al J Inf Dis.1994). We
evaluated the safety and efﬁcacy of alternate day Gan (5 mg/kg/
48H)/Fos (90 mg/kg/48H) in 50 pediatric AlloSCT recipients
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